173 related articles for article (PubMed ID: 30287427)
1. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.
Shillitoe B; Hollingsworth R; Foster M; Garcez T; Guzman D; Edgar JD; Buckland M
Clin Med (Lond); 2018 Oct; 18(5):364-370. PubMed ID: 30287427
[TBL] [Abstract][Full Text] [Related]
2. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
[TBL] [Abstract][Full Text] [Related]
3. The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017.
Shillitoe B; Bangs C; Guzman D; Gennery AR; Longhurst HJ; Slatter M; Edgar DM; Thomas M; Worth A; Huissoon A; Arkwright PD; Jolles S; Bourne H; Alachkar H; Savic S; Kumararatne DS; Patel S; Baxendale H; Noorani S; Yong PFK; Waruiru C; Pavaladurai V; Kelleher P; Herriot R; Bernatonienne J; Bhole M; Steele C; Hayman G; Richter A; Gompels M; Chopra C; Garcez T; Buckland M
Clin Exp Immunol; 2018 Jun; 192(3):284-291. PubMed ID: 29878323
[TBL] [Abstract][Full Text] [Related]
4. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
5. Inborn Errors of Immunity on the Island of Ireland - a Cross-Jurisdictional UKPID/ESID Registry Report.
Ryan P; Redenbaugh V; McGucken J; Kindle G; Devlin LA; Coulter T; Buckland MS; Seppänen MRJ; Conlon NP; Feighery C; Edgar JDM
J Clin Immunol; 2022 Aug; 42(6):1293-1299. PubMed ID: 35604475
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
[TBL] [Abstract][Full Text] [Related]
7. The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012.
Edgar JD; Buckland M; Guzman D; Conlon NP; Knerr V; Bangs C; Reiser V; Panahloo Z; Workman S; Slatter M; Gennery AR; Davies EG; Allwood Z; Arkwright PD; Helbert M; Longhurst HJ; Grigoriadou S; Devlin LA; Huissoon A; Krishna MT; Hackett S; Kumararatne DS; Condliffe AM; Baxendale H; Henderson K; Bethune C; Symons C; Wood P; Ford K; Patel S; Jain R; Jolles S; El-Shanawany T; Alachkar H; Herwadkar A; Sargur R; Shrimpton A; Hayman G; Abuzakouk M; Spickett G; Darroch CJ; Paulus S; Marshall SE; McDermott EM; Heath PT; Herriot R; Noorani S; Turner M; Khan S; Grimbacher B
Clin Exp Immunol; 2014 Jan; 175(1):68-78. PubMed ID: 23841717
[TBL] [Abstract][Full Text] [Related]
8. Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain.
Alsina L; Montoro JB; Moral PM; Neth O; Pica MO; Sánchez-Ramón S; Presa M; Oyagüez I; Casado MÁ; González-Granado LI
Eur J Health Econ; 2022 Apr; 23(3):551-558. PubMed ID: 34546485
[TBL] [Abstract][Full Text] [Related]
9. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
[No Abstract] [Full Text] [Related]
10. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
[No Abstract] [Full Text] [Related]
11. A retrospective review of immunology patients with primary and/or secondary immunodeficiency, demonstrating the benefits of the rapid transitioning from intravenous immunoglobulin to subcutaneous immunoglobulin at the onset of the COVID-19 pandemic.
Boyle T; Zaragoza R; Li J; Cvetanovski V; Weaver P; Hoyle P; Venkatesha V; Fernando SL
Intern Med J; 2023 Jul; 53(7):1256-1260. PubMed ID: 37092797
[TBL] [Abstract][Full Text] [Related]
12. Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese.
Kan AKC; Leung GMK; Chiang V; Au EYL; Lau CS; Li PH
Front Immunol; 2022; 13():984110. PubMed ID: 36591300
[TBL] [Abstract][Full Text] [Related]
13. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
[TBL] [Abstract][Full Text] [Related]
14. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
[TBL] [Abstract][Full Text] [Related]
15. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
Kobayashi RH; Litzman J; Rizvi S; Kreuwel H; Hoeller S; Gupta S
Immunotherapy; 2022 Mar; 14(4):259-270. PubMed ID: 34986666
[TBL] [Abstract][Full Text] [Related]
16. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
Pac M
Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
[TBL] [Abstract][Full Text] [Related]
17. A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis.
Hémar V; Rivière E; Greib C; Machelart I; Roucoules M; Prot C; Pellegrin JL; Viallard JF; Lazaro E
Immunotherapy; 2021 Dec; 13(18):1491-1499. PubMed ID: 34743547
[TBL] [Abstract][Full Text] [Related]
18. The case for a national service for primary immune deficiency disorders in New Zealand.
Ameratunga R; Steele R; Jordan A; Preece K; Barker R; Brewerton M; Lindsay K; Sinclair J; Storey P; Woon ST
N Z Med J; 2016 Jun; 129(1436):75-90. PubMed ID: 27355232
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry.
Abadeh A; Shehadeh S; Betschel S; Waserman S; Cameron DW; Cowan J
PLoS One; 2023; 18(11):e0294408. PubMed ID: 37971974
[TBL] [Abstract][Full Text] [Related]
20. The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008.
Gathmann B; Grimbacher B; Beauté J; Dudoit Y; Mahlaoui N; Fischer A; Knerr V; Kindle G;
Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):3-11. PubMed ID: 19630863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
